Sandoz Inc. Submits ANDA219346 for Review by FDA
Sandoz Inc. has submitted ANDA219346 for review, classified as a standard priority application.
| Drug | MOA / Company | Stage |
|---|---|---|
| Review | Sandoz | Lead |
Focal Asset
Review
Company
Sandoz
Indication
Not specified
Signal Score
6.8
Signal assessment
Signal strength
moderate
Confidence level
moderate
Why it matters
The submission of ANDA219346 by Sandoz Inc. represents a significant move to enhance their generic portfolio, which could disrupt pricing and competition in the generic drug market. Pharma strategy teams should closely monitor this development to anticipate shifts in market dynamics.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any subsequent approvals or market entries related to ANDA219346.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.